Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > A little decision analysis
View:
Post by westcoast1000 on Feb 12, 2023 2:14pm

A little decision analysis

Let us try a little analysis to think through the expected value of some representative potential scenarios involving ONCY getting a buyout deal over the next year.
 
We can use probabilities, which can be seen as degrees of belief, not measurable facts in the world, and which is the only conception of probability that works for events without large data and experience.
 
To begin, what is the p that the company is not actually in negotiations, but rather just in a funk with nothing to say. To avoid over-confidence, we can say it is .1 or a 10 percent chance, even though I strongly believe they are negotiating. The payoff for that scenario is simply some number around current market cap but with more shares issued to cover costs for a year.
 
Next, what is the p that the company is in negotiations, but cannot extract an acceptable offer from big pharma this year. Let us say the minimum offer the company would accept would be $ 2 bil US. We can again conservatively say that probability is .2 or 20 percent. The payoff is again somewhere around the current market cap, but with but with more shares issued to cover costs for a year.
 
Next what is the p there is an acceptable offer this year of between $2 bil and $4 bil. We can put that at .3 and call the expected payoff to be $3 bil as the mid point in the range, paid out in 2023.
 
Next what is the p there is an acceptable offer this year of between $4 bil and $6 bil. We can put that at .2 and call the expected payoff to be $5 bil as the mid point in the range, paid out in 2023.
 
Next what is the p there is an acceptable offer this year of between $6 bil and $8 bil. We can put that at .2 and call the expected payoff to be $ 7 bil as the mid point in the range, paid out in 2023.
 
The expected value of the payoffs that involve a buyout is:
 .3 x 3 b + .2 x 5 b + .2 x 7 b
= .9 + 1. + 1.4
= $ 3.3 bil expected value, even accounting for 30 percent chance there is no deal. One could include some negative payoffs for the scenarios in which there is no deal if you care to do so.
 
You can put in your own probabilities and your own payoffs to evaluate the expected value, given your own assumptions.
 
You could also introduce your own scenarios regarding a partnership that is not a complete buyout and your guesses on its expected value.
In sum, we face considerable uncertainty, but most scenarios look good, and the expected value is very encouraging. I am tempted to buy more but I am at the upper limit.
Comment by jimsenior on Feb 12, 2023 4:46pm
Thank you for an excellent post. If the 3.3B US is attained and it seems to be a good working number, a purchase of shares (given the current price) would pay off handsomely. Yet, I am not inclined to add at this point. The nonsense with the presentation, and not knowing the status of the ATM action leaves me somewhat cautious; not to mention the lack of clarity with AN, & Pfizer. May revisit ...more  
Comment by westcoast1000 on Feb 12, 2023 6:41pm
Over on the Yahoo board, under the leadership of the tiresome big guy that many of us have been hearing from on Yahoo V2 for well over five years, the main sentiment is that the company is a scam that is manipulated to create a retirement for Matt. The main argument seems to be resentment over dilution over the last 5 years. That dilution has been substantial, but also led to some some very low ...more  
Comment by canadafan on Feb 12, 2023 7:28pm
I agree on the " values" of the last corporation updates. Specifically the Pancreatic cancer results. They afterall were discussed in deatai with the Kol key opinion leaders, telecfonference. Although quite medical in context, quite well explained & very enthusiastic. Then can A.N. Update giving " further encouraging signs of Pelareorep as a cancer co- therapy" now" ...more  
Comment by jimsenior on Feb 12, 2023 8:00pm
I am having trouble navigating this site. I think there is only one universe, and that that universe is flat, so take the following with a grain of salt. The mind numbing blather over there is purposeful, and somewhat effective if you let it be. Inexorable repetition is their mantra. I recently decided yahoo in its entirety is not worth visiting, so their negativity has been rendered meaningless. ...more  
Comment by westcoast1000 on Feb 13, 2023 3:21pm
Clearly my post on DA for ONCY gave a big boost to the share price. Just kidding! Very few are reading this blog.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities